ES2542744T3 - Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural - Google Patents

Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural Download PDF

Info

Publication number
ES2542744T3
ES2542744T3 ES10842428.4T ES10842428T ES2542744T3 ES 2542744 T3 ES2542744 T3 ES 2542744T3 ES 10842428 T ES10842428 T ES 10842428T ES 2542744 T3 ES2542744 T3 ES 2542744T3
Authority
ES
Spain
Prior art keywords
nucleic acid
restriction enzyme
region
cdr3
regions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10842428.4T
Other languages
English (en)
Inventor
Nicolas Fischer
Marie Kosco-Vilbois
Ulla Ravn
Franck Gueneau
Sophie Venet-Bonnot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novimmune SA
Original Assignee
Novimmune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/784,190 external-priority patent/US8921281B2/en
Application filed by Novimmune SA filed Critical Novimmune SA
Application granted granted Critical
Publication of ES2542744T3 publication Critical patent/ES2542744T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un método para producir una colección de ácidos nucleicos, en el que cada ácido nucleico codifica un dominio variable de inmunoglobulina humana que comprende una pluralidad de secuencias de región determinante de complementariedad 3 (CDR3) aisladas por separado del repertorio de dominio variable de inmunoglobulina de una especie de mamífero o un mamífero no humano inmunizado, comprendiendo el método: (a) proporcionar una pluralidad de secuencias de ácido nucleico de Marco conservado Aceptor que codifican dominios variables de inmunoglobulina humana distintos, comprendiendo cada secuencia de ácido nucleico de Marco conservado Aceptor una primera región marco conservada (FR1), una segunda región marco conservada (FR2), una tercera región marco conservada (FR3) y una cuarta región marco conservada (FR4), en las que las regiones FR1 y FR2 están intercaladas con una región determinante de complementariedad 1 (CDR1), las regiones FR2 y FR3 están intercaladas con una región determinante de complementariedad 2 (CDR2), y las regiones FR3 y FR4 están intercaladas con una secuencia de ácido nucleico de relleno que comprende al menos dos sitios de reconocimiento de enzimas de restricción de Tipo IIs intercalados con una secuencia de ácido nucleico aleatoria que codifica un polipéptido que realiza la función de una región CDR3 de inmunoglobulina variable; (b) proporcionar una pluralidad de secuencias de ácido nucleico diversificadas que codifican secuencias de región determinante de complementariedad 3 (CDR3) del repertorio de inmunoglobulina de especie de mamífero o el mamífero no humano inmunizado en el que cada una de la pluralidad de secuencias de ácido nucleico diversificadas comprende un sitio de reconocimiento de enzimas de restricción de Tipo IIs en cada extremo; (c) digerir cada una de la pluralidad de secuencias de ácido nucleico que codifican las regiones CDR3 usando una enzima de restricción de Tipo IIs que se une con el sitio de reconocimiento de enzimas de restricción de Tipo IIs de la etapa (b) y digerir la secuencia de ácido nucleico de relleno de la etapa (a) del Marco conservado Aceptor usando una enzima de restricción de Tipo IIs que se une con el sitio de reconocimiento de enzimas de restricción de Tipo IIs de la etapa (a); y (d) ligar las secuencias de ácido nucleico digeridas que codifican las regiones CDR3 o las secuencias de aminoácidos de la etapa (c) en el Marco conservado Aceptor digerido de la etapa (c) de modo que las regiones FR3 y FR4 estén intercaladas con las secuencias de ácido nucleico que codifican la región CDR3 o la secuencia de aminoácidos que puede cumplir el papel de una región CDR3 y se restauran secuencias que codifican un dominio variable de inmunoglobulina completo que no contienen los sitios de reconocimiento de enzimas de restricción de Tipo IIs de las etapas (a) y (b).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42

Claims (1)

  1. imagen1
    imagen2
ES10842428.4T 2009-12-17 2010-11-23 Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural Active ES2542744T3 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US28733609P 2009-12-17 2009-12-17
US287336P 2009-12-17
US31479410P 2010-03-17 2010-03-17
US314794P 2010-03-17
US784190 2010-05-20
US12/784,190 US8921281B2 (en) 2009-05-20 2010-05-20 Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
US37957110P 2010-09-02 2010-09-02
US379571P 2010-09-02
PCT/US2010/057780 WO2011084255A2 (en) 2009-12-17 2010-11-23 Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants

Publications (1)

Publication Number Publication Date
ES2542744T3 true ES2542744T3 (es) 2015-08-11

Family

ID=44306015

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10842428.4T Active ES2542744T3 (es) 2009-12-17 2010-11-23 Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural

Country Status (3)

Country Link
EP (1) EP2513312B1 (es)
ES (1) ES2542744T3 (es)
WO (1) WO2011084255A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2767135T3 (es) 2011-10-19 2020-06-16 Novimmune Sa Métodos para purificar anticuerpos
PT2925782T (pt) 2012-12-03 2020-04-22 Novimmune Sa Anticorpos anti-cd47 e métodos de utilização destes
CN114249831A (zh) 2015-03-13 2022-03-29 诺夫免疫股份有限公司 纯化双特异性抗体的方法
WO2018083535A1 (en) 2016-11-04 2018-05-11 Novimmune Sa Anti-cd19 antibodies and methods of use thereof
WO2018215835A1 (en) 2017-05-26 2018-11-29 Novimmune Sa Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
WO2019175658A1 (en) 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
TW202003569A (zh) 2018-03-30 2020-01-16 荷蘭商美勒斯公司 多價抗體
IL305827A (en) 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
JP2024512574A (ja) 2021-03-22 2024-03-19 ノビミューン エスアー Ｃｄ４７およびｐｄ－ｌ１を標的とする二重特異性抗体ならびにその使用方法
WO2023178357A1 (en) 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2024084052A1 (en) 2022-10-21 2024-04-25 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US8288322B2 (en) * 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
WO2003035842A2 (en) * 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
CN101720368A (zh) * 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
BRPI1011195B1 (pt) * 2009-05-20 2020-10-13 Novimmune S.A métodos para produzir uma coleção de ácidos nucleicos

Also Published As

Publication number Publication date
WO2011084255A2 (en) 2011-07-14
WO2011084255A3 (en) 2011-10-06
EP2513312A4 (en) 2013-05-15
EP2513312A2 (en) 2012-10-24
EP2513312B1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
ES2542744T3 (es) Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural
JP2009153527A5 (es)
PE20190976A1 (es) Anticuerpos de union a cd3
CY1124341T1 (el) Ποντικοι me εξανθρωπισμενη καθολικη ελαφρια αλυσιδα
CY1120770T1 (el) Ζωα πλην του ανθρωπου με τροποποιημενες αλληλουχιες βαριας αλυσιδας της ανοσοσφαιρινης
HRP20202042T1 (hr) Modulacija tumorske imunosti
FI2726510T3 (fi) Kaksoiskohdennus
BR112017010744A2 (pt) anticorpos monoclonais anti-pd-1 e método de obtenção dos mesmos
BR112018010385A2 (pt) anticorpo, receptor de antígeno quimérico, ácido nucleico, célula recombinante, processo para produção de um anticorpo ou um receptor de antígeno quimérico, composição, e, método para detecção de uma célula que expressa cll-1, para diagnóstico de uma doença, para inibição de divisão da célula e para tratamento de um câncer.
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
HRP20160158T4 (hr) Topiva protutijela koja sadrže samo teške lance
ECSP10010029A (es) Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano
DK1144616T4 (da) Fremgangsmåde til fremstilling af antistoffragmenter
WO2012092374A3 (en) Express humanization of antibodies
HRP20230490T1 (hr) Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina
EA201791366A1 (ru) Антитела к c5 и способы их применения
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
WO2006052591A3 (en) Anti-properdin antibodies, and methods for making and using same
CA2808482C (en) Methods for the generation of multispecific and multivalent antibodies
RU2014127339A (ru) Мыши с гуманизированной легкой цепью
NZ581418A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
UY30524A1 (es) Anticuerpos dirigidos a avb(beta)6 y sus usos
CY1116037T1 (el) Αντισωματα κατα της ακτιβινης α και χρησεις αυτων
CN103562403A8 (zh) 识别肿瘤起始细胞的抗体和抗原及其应用
AR065420A1 (es) Anticuerpos anti-il-23 p19 de ingenieria